Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.37 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76712 | 0.83 | NPC1 (0.50) | OPRM1SIGMAR1OPRL1RAB9ANPC1 | |
| SCHEMBL30421418 | 0.70 | GRM5 (0.54) | GAAMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL25845296 | 0.63 | SMN1; SMN2 (0.81) | GAAKMT2AGRM5RAB9ANPC1 | |
| SCHEMBL12362754 | 0.63 | RAB9A (0.45) | GAAMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL27170422 | 0.63 | NPC1 (0.74) | GAAMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4089018 | 0.62 | ESR1 (0.43) | MEN1KMT2ARAB9AKDM4EESR1 | |
| SCHEMBL29348826 | 0.62 | ALDH1A1 (0.36) | GAAMEN1KMT2AOPRM1SIGMAR1 | |
| SCHEMBL12009549 | 0.61 | ESR1 (0.52) | GAAMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL16264819 | 0.61 | AR (0.52) | GAAMEN1KMT2AGRM5OPRM1 | |
| SCHEMBL5256770 | 0.61 | RAB9A (0.53) | GAAKMT2ARAB9AKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | claimed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | claimed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | claimed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | GAA 3162/4885MEN1 434/4885KMT2A 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.